Department of Pharmacology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Department of Humanistic Nursing, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Microb Pathog. 2024 Mar;188:106563. doi: 10.1016/j.micpath.2024.106563. Epub 2024 Feb 6.
BACKGROUND: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that primarily affects the joints. Individuals at risk for RA and people with RA develop intestinal dysbiosis. The changes in intestinal flora composition in preclinical and confirmed RA patients suggest that intestinal flora imbalance may play an important role in the induction and persistence of RA. METHODS: Based on the current research on the interaction between RA and intestinal microbiota, intestinal microbiota metabolites and intestinal barrier changes. This paper systematically summarized the changes in intestinal microbiota in RA patients, the metabolites of intestinal flora, and the influence mechanism of intestinal barrier on RA, and further discussed the influence of drugs for RA on intestinal flora and its mechanism of action. RESULTS: Compared with healthy controls, α diversity analysis of intestinal flora showed no significant difference, β diversity analysis showed significant differences. The intestinal flora produces bioactive metabolites, such as short-chain fatty acids and aromatic amino acids, which have anti-inflammatory effects. Abnormal intestinal flora leads to impaired barrier function and mucosal immune dysfunction, promoting the development of inflammation. Traditional Chinese medicine (TCM) and chemical drugs can also alleviate RA by regulating intestinal flora, intestinal flora metabolites, and intestinal barrier. Intestinal flora is closely related to the pathogenesis of RA and may become potential biomarkers for the diagnosis and treatment of RA. CONCLUSIONS: Intestinal flora and its metabolites play an important role in the pathogenesis of autoimmune diseases such as RA, and are expected to become a new target for clinical diagnosis and treatment, providing a new idea for targeted treatment of RA.
背景:类风湿关节炎(RA)是一种主要影响关节的自身免疫性炎症性疾病。RA 的高危人群和 RA 患者会出现肠道菌群失调。临床前和确诊的 RA 患者肠道菌群组成的变化表明,肠道菌群失衡可能在 RA 的诱导和持续中发挥重要作用。
方法:本文基于 RA 与肠道微生物群、肠道菌群代谢物和肠道屏障变化的交互作用的当前研究,系统总结了 RA 患者肠道菌群、菌群代谢物的变化,以及肠道屏障对 RA 的影响机制,并进一步探讨了 RA 药物对肠道菌群的影响及其作用机制。
结果:与健康对照组相比,肠道菌群的 α 多样性分析无显著差异,β 多样性分析有显著差异。肠道菌群产生具有抗炎作用的生物活性代谢物,如短链脂肪酸和芳香族氨基酸。异常的肠道菌群导致屏障功能受损和黏膜免疫功能障碍,促进炎症的发展。中药和化学药物也可以通过调节肠道菌群、肠道菌群代谢物和肠道屏障来缓解 RA。肠道菌群与 RA 的发病机制密切相关,可能成为 RA 诊断和治疗的潜在生物标志物。
结论:肠道菌群及其代谢物在 RA 等自身免疫性疾病的发病机制中发挥着重要作用,有望成为临床诊断和治疗的新靶点,为 RA 的靶向治疗提供了新的思路。
Front Cell Infect Microbiol. 2023
Healthcare (Basel). 2025-8-8
Biochem Biophys Rep. 2025-7-12
Sci China Life Sci. 2025-3
Front Pharmacol. 2024-8-19
Am J Physiol Gastrointest Liver Physiol. 2024-6-1